http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012103522-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46700f8a229dd51f083e00d731ad4799 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8852128599ab180c45ac92a260c2a39 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| filingDate | 2012-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b412cfe2a46c10d368033b4e2bbca91c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37dabc9fcfdc26f4ab5533a4d6dd647b |
| publicationDate | 2012-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2012103522-A2 |
| titleOfInvention | Materials and methods for identifying patients susceptible to developing taxane induced neuropthy |
| abstract | A randomized phase III study with a planned accmal (n=4950); GWAS performed ors 2204 patients to compare genotypes with efficacy and toxicities. The phenotype for this study is time to first grade 2-4 neuropathy. GVVAS is conducted using the Xnfmium HumanOmnil platform from Illumma which assessed 1.2 million SNPs per patient. Comparisons are made using Cox regression analysis with correction for multiple comparisons (Bonferroni) and established clinical trial co-variates (race, age, tumor size, LN status). Toxicity data indicates that 576 patients experienced grade 2-4 neuropathy and 1633 did not. Clinical predictors for neuropathy include age (12.9% increase with each decade; p=0.004) and African American race (HR=2.1; p=4.5 x 10 -11 ). Six SNPs with MAF>5% demonstrate associations with neuropathy (ρ<5χ 10 -7 ). These SNPs reside in two genes: RWDD3 and TECTA. A missense SNP in RWDD3 demonstrates % neuropathy at 15 months follow-up: 27% for homozygous wild-type, 40% for heterozygotes, and 60% for homozygous variant (allele dose-effect: HR=1.5; p=8.5 χ 10 -8 ). Multiple other SNPs with MAF<5% were also associated with neuropathy (p<5x 10 -7 ). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114783528-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114783528-B |
| priorityDate | 2011-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 130.